Company profile: Werewolf Therapeutics
1.1 - Company Overview
Company description
- Provider of oncology biotherapeutics developing systemically delivered, conditionally activated INDUKINE cytokine therapies, including WTX-124 (IL-2), WTX-330 (IL-12), JZP898 (IFNα), WTX-712 (IL-21), and WTX-518 (IL-18), designed to minimize severe toxicities and maximize clinical benefit in multiple or refractory tumor types, and using PREDATOR protein engineering to create immuno-oncology, autoimmune, and inflammatory product candidates.
Products and services
- JZP898 (Formerly WTX-613): A custom-engineered, systemically delivered, conditionally activated Interferon alpha (IFNα) INDUKINE molecule developed to minimize severe toxicities and maximize clinical benefit in refractory and/or immunologically unresponsive tumors
- WTX-330: An advanced, systemically delivered, conditionally activated Interleukin-12 (IL-12) INDUKINE molecule architected to minimize severe toxicities and maximize clinical benefit in refractory and/or immunologically unresponsive tumors
- WTX-124: A precision-engineered, systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule engineered to minimize severe toxicities and maximize clinical benefit in multiple tumor types
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Werewolf Therapeutics
Craniovation
HQ: United States
Website
- Description: Provider of a minimally invasive light-delivery device to treat aggressive brain tumors, including those deep within the brain, allowing patients to avoid invasive brain surgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Craniovation company profile →
Ikonisys
HQ: United States
Website
- Description: Provider of fully automated microscopy platforms and FISH-based diagnostic applications for early, accurate, non-invasive disease detection, including Ikoniscope20 for rare-cell detection and Ikoniscope20max with high-volume slide loading, plus oncoFISH solutions for bladder cancer (urine), HER2 status, cervical 3q26 gain in LSIL/ASCUS, and ALK gene rearrangements in non-small cell lung carcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ikonisys company profile →
Xoft
HQ: United States
Website
- Description: Provider of electronic brachytherapy (eBx) systems for radiation oncology, including the Elekta Xoft Axxent system with miniaturized X-ray source, Axxent Controller, SPX Controller for surface treatments, Axxent X-ray Source, balloon and extended balloon applicators for intracavitary and intraoperative therapy, and Radion Hub Peer Review cloud software for network-wide peer review to improve patient safety and quality care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xoft company profile →
Kolltan
HQ: United States
Website
- Description: Provider of novel monoclonal antibody oncology therapeutics targeting receptor tyrosine kinases (RTKs); develops next-generation mAb drugs based on seminal discoveries from Dr. Joseph Schlessinger's Yale Pharmacology lab; founded in 2007 as a private company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kolltan company profile →
Perspective Therapeutics
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer theranostics and targeted alpha-particle radiotherapy, including Pb-203 diagnostics and Pb-212 treatment via targeting peptides. Offers clinical programs VMT-α-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, and a proprietary Pb-212 isotope generator to secure key isotopes for clinical trials and commercial operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Perspective Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Werewolf Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Werewolf Therapeutics
2.2 - Growth funds investing in similar companies to Werewolf Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Werewolf Therapeutics
4.2 - Public trading comparable groups for Werewolf Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →